Much of the available data regarding the therapeutic use of psychedelics for mental health disorders remains introductory; however, momentum is building with the potential to offer unique treatments for many complex mental health disorders.
New pharmaceuticals to treat sickle cell disease (SCD) are steadily improving the health and wellbeing of many people living with this chronic disorder. It is hoped that revolutionary gene therapies now in clinical trials will be able to cure more SCD patients. The r...
Read More
GPT-4 features stronger safety and privacy guardrails, longer input and output text, and more accurate, detailed, and concise responses for nuanced questions. Although it offers exciting opportunities for insurance and countless other industries, its potential provid...
Read More
Many health insurers exclude experimental treatments without clearly defining which treatments they would consider experimental. In this Global Health Brief, RGA's Colin Weston discusses the need for clear definitions in policy language. He also explores how drugs, t...
Read More
Asset-intensive reinsurance is growing in popularity in the life insurance industry, and it is more important than ever for insurers to seek out trusted partners when selecting an asset-intensive reinsurer.
Explore RGActual, our magazine covering innovation, experience, and development for insurance professionals. In this issue, we continue our celebration of 50 years of positive impact.
Read More
Although much of the spotlight is currently on ChatGPT, the generative artificial intelligence (AI) landscape is much broader. In this article, RGA's Neil Parkin provides an overview of potential opportunities emerging from AI for insurers.
The Geneva Association recently published a comprehensive report on the ongoing mental health crisis and the insurance industry’s role and responsibility in promoting mental wellbeing to help address this growing societal challenge.
